Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance

Neuropharmacology

Volumn 47, Issue 7, 2004, Pages 1081-1092

  Boess, Frank G ^a   Hendrix, Martin ^a   Van Der Staay, Franz Josef ^a   Erb, Christina ^a   Schreiber, Rudy ^a   Van Staveren, Wilma ^b   De Vente, Jan ^b   Prickaerts, Jos ^b   Blokland, Arjan ^b   Koenig, Gerhard ^a  

^a BAYER PHARMA AG   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

cGMP; Learning; Long term potentiation; LTP; Memory; PDE2; Phosphodiesterase 2

Indexed keywords

BAY 607550; CYCLIC GMP; PHOSPHODIESTERASE; TRIAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INHIBITION; MALE; MAZE TEST; MEMORY CELL; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; SYNAPTIC TRANSMISSION;

ANIMALS; CATTLE; CHO CELLS; CRICETINAE; CYCLIC AMP; CYCLIC GMP; EXONUCLEASES; GUINEA PIGS; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; NEURONAL PLASTICITY; NEURONS; PHOSPHODIESTERASE INHIBITORS; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 8844220521     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.07.040     Document Type: Article

References (74)

1. Ahem G.P., Klyachko V.A., Jackson M.B. cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci. 25:2002;510-517
2. Arancio O., Kandel E.R., Hawkins R.D. Activity-dependent long-term enhancement of transmitter release by presynaptic 3′, 5′-cyclic GMP in cultured hippocampal neurons. Nature. 376:1995;74-80
3. Arancio O., Antonova I., Gambaryan S., Lohmann S.M., Wood J.S., Lawrence D.S., Hawkins R.D. Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. J. Neurosci. 21:2001;143-149
4. Baltrons M.A., Pedraza C.E., Heneka M.T., García A. β-Amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol. Dis. 10:2002;139-149
5. Baratti C.M., Boccia M.M. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav. Pharmacol. 10:1999;731-737
6. Bentley J.K., Juilfs D.M., Uhler M.D. Nerve growth factor inhibits PC12 cell PDE2 phosphodiesterase activity and increases PDE2 binding to phosphoproteins. J. Neurochem. 76:2001;1252-1263
7. Bernabeu R., Schmitz P., Faillace M.P., Izquierdo I., Medina J.H. Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport. 7:1996;585-588
8. 6 receptors stably expressed in HEK293 cells. Neuropharmacology. 36:1997a;713-720
9. 3 receptor using site directed mutagenesis: importance of glutamate 106. Neuropharmacology. 36:1997b;637-647
10. Böhme G.A., Bon C., Stutzmann J.M., Doble A., Blanchard J.C. Possible involvement of nitric oxide in long-term potentiation. Eur. J. Pharmacol. 199:1991;379-381
11. 2C receptors. Br. J. Pharmacol. 115:1995;622-628
12. Bonkale W.L., Winblad B., Ravid R., Cowburn R.F. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci. Lett. 187:1995;5-8
13. 3H]cGMP binding in brain staged for Alzheimer's disease pathologies. Biochem. Soc. Trans. 28:2000;A38
14. Boulton C.L., Southam E., Garthwaite J. Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience. 69:1995;699-703
15. Bredt D.S., Glatt C.E., Hwang P.M., Fotuhi M., Dawson T.M., Snyder S.H. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron. 7:1991;615-624
16. Buckley N.J., Bonner T.I., Buckley C.M., Brann M.R. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 35:1989;469-476
17. Burgunder J.-M., Cheung P.T. Expression of soluble guanylyl cyclase gene in adult rat brain. Eur. J. Neurosci. 6:1994;211-217
18. Caiolfa V.R., Gill D., Parola A.H. Probing the active site of adenosine deaminase by a pH responsive fluorescent competitive inhibitor. Biophys. Chem. 70:1998;41-56
19. Castellano C., Cestari V., Ciamei A. NMDA receptors and learning and memory processes. Curr. Drug Targets. 2:2001;273-283
20. Collingridge G.L., Bliss T.V. Memories of NMDA receptors and LTP. Trends Neurosci. 18:1995;54-56
21. De Backer M.D., Gommeren W., Moereels H., Nobels G., Van Gompel P., Leysen J.E., Luyten W.H. Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem. Biophys. Res. Commun. 197:1993;1601-1608
22. De Vente J.D., Steinbusch H.W.M. On the stimulation of soluble and particulate guanylate cyclase in the rat brain and the involvement of nitric oxide as studied by cGMP immunocytochemistry. Acta Histochem. 92:1992;13-38
23. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats 1: behavioral data. Behav. Brain Res. 31:1988;47-59
24. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14:1991;60-67
25. Gerlai R. A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Behav. Brain Res. 95:1998;91-101
26. 4 receptors in guinea-pig and rat brain. Br. J. Pharmacol. 109:1993;618-624
27. Hawkins R.D., Son H., Arancio O. Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Prog. Brain Res. 118:1998;155-172
28. Holscher C. Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Trends Neurosci. 20:1997;298-303
29. Holscher C., Rose S.P. Inhibiting synthesis of the putative retrograde messenger nitric oxide results in amnesia in a passive avoidance task in the chick. Brain Res. 619:1993;189-194
30. Libert F., Van Sande J., Lefort A., Czernilofsky A., Dumont J.E., Vassart G., Ensinger H.A., Mendla K.D. Cloning and functional characterization of a human A1 adenosine receptor. Biochem. Biophys. Res. Commun. 187:1992;919-926
31. 3H]kainic acid to receptor sites in rat brain. Mol. Pharmacol. 15:1979;492-505
32. Loughney K., Hill T.R., Florio V.A., Uher L., Rosman G.J., Wolda S.L., Jones B.A., Howard M.L., McAllister-Lucas L.M., Sonnenburg W.K., Francis S.H., Corbin J.D., Beavo J.A., Ferguson K. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene. 216:1998;139-147
33. Lu Y., Kandel E.R., Hawkins R.D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci. 19:1999;10250-10261
34. Lynch M.A. Long-term potentiation and memory. Physiol. Rev. 84:2004;87-136
35. Martin G.R., Humphrey P.P. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology. 33:1994;261-273
36. 3H]muscimol binding site on purified benzodiazepine receptor. J. Neurochem. 41:1983;1183-1185
37. Martins T.J., Mumby M.C., Beavo J.A. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J. Biol. Chem. 257:1982;1973-1979
38. Matusoka I., Giuili G., Poyard M., Stengel D., Parma J., Guellaen G., Hanoune J. Localization of adenylyl and guanylyl cyclase in rat brain by in situ hybridization: comparison with calmodulin mRNA distribution. J. Neurosci. 12:1992;3350-3360
39. Mery P.-F., Fischmeister R. EHNA reverses the inhibitory effect of cGMP on cardiac L-type Ca current via PDE II inhibition. FASEB J. 8:1994;A82
40. Monfort P., Munoz M.D., Kosenko E., Felipo V. Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. J. Neurosci. 22:2002;10116-10122
41. Nadarajah B. The effect of pralidoxime chloride in the assay of acetylcholinesterase using 5,5′-dithio-bis(2-nitrobenzoic acid) (Ellman's reagent). J. Anal. Toxicol. 16:1992;192-193
42. O'Dell T.J., Hawkins R.D., Kandel E.R., Arancio O. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc. Natl. Acad. Sci. USA. 88:1991;11285-11289
43. O'Donnell J.M. William Harvey research conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Expert Opin. Investig. Drugs. 9:2000;621-625
44. 3H]AMPA binding to glutamate receptor subpopulations in rat brain. Brain Res. 402:1987;243-254
45. Otmakhov N., Khibnik L., Otmakhova N., Carpenter S., Riahi S., Asrican B., Lisman J. Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent. J. Neurophysiol. 91:2004;1955-1962
46. Podzuweit T., Nennstiel P., Müller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterase by EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine). Cell Sign. 7:1995;733-738
47. Prickaerts J., Steinbusch H.W.M., Smits J.F.M., De Vente J. Possible role of nitric oxide-cyclic GMP pathway in object recognition, effects of 7-nitroindazole and zaprinast. Eur. J. Pharmacol. 337:1997;125-136
48. Prickaerts J., De Vente J., Honig W., Steinbusch H.W.M., Blokland A. Cyclic GMP, but not cyclic AMP, in rats hippocampus is involved in early stages of object memory consolidation. Eur. J. Pharmacol. 436:2002a;83-87
49. Prickaerts J., Van Staveren W.C.G., Şik A., Markerink-Van Ittersum M., Niewöhner U., Van der Staay F.J., Blokland A., De Vente J. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience. 113:2002b;349-359
50. Repaske D.R., Corbin J.G., Conti M., Goy M.F. A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. Neuroscience. 56:1993;673-686
51. Saenz de Tejada I., Angulo J., Cuevas P., Fernandez A., Moncada I., Allona A., Lledo E., Korschen H.G., Niewohner U., Haning H., Pages E., Bischoff E. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. 13:2001;282-290
52. Savchenko A., Barnes S., Kramer R.H. Cyclic-nucleotide-gated channels mediate synaptic feedback by nitric oxide. Nature. 390:1997;694-698
53. Schuman E.M., Madison D.V. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science. 254:1991;1503-1506
54. 7 serotonin receptor subtype. J. Biol. Chem. 268:1993;18200-18204
55. 3H]CGP39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur. J. Pharmacol. 192:1991;19-24
56. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 12:2000;174-179
57. Son H., Hawkins R.D., Martin K., Kiebler M., Huang P.L., Fishman M.C., Kandel E.R. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell. 87:1996;1015-1023
58. 3H]flunitrazepam binding. Life Sci. 24:1979;351-357
59. Stasch J.P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., Perzborn E., Schramm M., Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, Bay 41-8543: in vitro studies. Br. J. Pharmacol. 135:2002;333-343
60. 1A receptor agonist Bay x 3702 prevents staurosporine-induced apoptosis. Eur. J. Pharmacol. 355:1998;95-101
61. Suvarna N.U., O'Donnell J.M. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J. Pharmacol. Exp. Ther. 302:2002;249-256
62. Thor D.H., Holloway W.R. Social memory of the male laboratory rat. J. Comp. Physiol. Psychol. 96:1982;1000-1006
63. Urban P., Andersen J.K., Hsu H.P., Pompon D. Comparative membrane locations and activities of human monoamine oxidases expressed in yeast. FEBS Lett. 286:1991;142-146
64. Vallebuona F., Raiteri M. Extracellular cGMP in the hippocampus of freely moving rats as an index of nitric oxide (NO) synthase activity. J. Neurosci. 14:1994;134-139
65. Van Staveren W.C.G., Markerink-van Ittersum M., Steinbusch H.W.M., De Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res. 888:2001;275-286
66. 3H]-CGS 21680 binding. Br. J. Pharmacol. 117:1996;1693-1701
67. Vargeese C., Sarma M.S., Pragnacharyulu P.V., Abushanab E., Li S.Y., Stoeckler J.D. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl) adenine. J. Med. Chem. 37:1994;3844-3849
68. Wang X., Robinson P.J. cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J. Neurochem. 68:1997;443-456
69. Wilsch V.W., Behnisch T., Jager T., Reymann K.G., Balschun D. When are class I metabotropic glutamate receptors necessary for long-term potentiation? J. Neurosci. 18:1998;6071-6080
70. 2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J. Neurochem. 69:1997;1449-1458
71. Wykes V., Bellamy T.C., Garthwaite J. Kinetics of nitric oxide-cyclic GMP signalling in CNS cells and its possible regulation by cyclic GMP. J. Neurochem. 83:2002;37-47
72. Yamada K., Hiramatsu M., Noda Y., Mamiya T., Murai M., Kameyama T., Komori Y., Nikai T., Sugihara H., Nabeshima T. Role of nitric oxide and cyclic-GMP in the dizolcipine-induced impairment of spontaneous-alternation behavior in mice. Neuroscience. 74:1996;365-374
73. 3H](R)alpha- methylhistamine binding to rat tissues. Jap. J. Pharmacol. 65:1994;107-112
74. Zhuo M., Hu Y., Schultz C., Kandel E.R., Hawkins R.D. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature. 368:1994;635-639